RecruitingPhase 1NCT06724835

Treating Nectin-4-positive Advanced Breast Cancer with XKDCT293 (Nectin-4-CAR-T)

A Single-center, Single-arm, Dose-escalation Exploratory Clinical Trial of the Safety, Efficacy, and Pharmacokinetics of XKDCT293 (Nectin-4-CAR-T) in Nectin-4-positive Advanced Breast Cancer

Sponsor

Shenzhen Celconta Life Science Co., Ltd.

Enrollment

18 participants

Start Date

Mar 11, 2024

Study Type

INTERVENTIONAL

Conditions

Advanced Breast Cancer

Summary

A single-center, single-arm, dose-escalation exploratory clinical trial of the safety, efficacy, and pharmacokinetics of XKDCT 293 (Nectin-4-CAR-T) in Nectin-4-positive advanced breast cancer

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new CAR-T cell therapy (a form of immunotherapy where your own immune cells are engineered to attack cancer) called XKDCT293, which targets the Nectin-4 protein found on certain breast cancer cells. **You may be eligible if...** - Age 18–75 - Have locally advanced or metastatic (spread) breast cancer - Your cancer tests positive for Nectin-4 protein - Have tried and failed prior standard treatments for breast cancer - Have adequate organ function **You may NOT be eligible if...** - Your cancer does not express Nectin-4 - Have active brain metastases (cancer in the brain) - Have serious infections, autoimmune disease, or other major health problems - Are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.